NCT02571725 2025-05-23PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian CancerNew Mexico Cancer Research AlliancePhase 1/2 Active not recruiting50 enrolled
NCT02658214 2020-08-20Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsAstraZenecaPhase 1 Completed32 enrolled